FIGURE

Fig. 4

ID

ZDB-FIG-190708-3

Publication

Xu et al., 2017 - JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide

Other Figures

All Figure Page

Back to All Figure Page

Fig. 4

JAM-A activated TGF-β/NODAL signaling. (A,B) In JAM-A-transfected DB cells (A) and DLBCL patients (B), JAM-A overexpression was related to activation of TGF-β/NODAL signaling. (C) As assessed by Whole-mount in Situ Hybridization and real-time quantitative RT-PCR, ndr-1 and ndr-2 were increased in jam-1-overexpressing zebrafish. WT, wild type. (D) JAM-A upregulated NODAL expression, which was restored by specific TGF-β/NODAL/Smad inhibitor SB431542 or JAM-A ShRNA. SB431542 abrogated JAM-A-induced lymphoma cell invasion (E) JAM-A was the highest in patients with involvement of endoderm-derived organs, followed by those with involvement of mesoderm- and ectoderm-derived organs. (F) JAM-A correlated with increased NODAL expression in primary lymph nodes, as well as in secondary lesions. Data in (C) are representative of three independent experiments.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Sci. Rep.